At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
BIBF1120 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating BIBF1120 and Placebo for Ovarian Neoplasms. Completed, enrolled 89 participants across 11 sites.
Detailed Summary
The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedJul 2008
Primary CompletionSep 2008
Study CompletionMar 2014
TodayJul 2026
First PostedJul 4, 2008
Enrollment StartMar 1, 2006
Primary CompletionSep 1, 2008
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.0 years ago
Interventions
BIBF1120drug
Placebodrug